Drugs / GSK835726
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00605852 | Oct 2007 → May 2008 | seasonal allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00972504 Comparator | Jun → Aug 2009 | seasonal allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00851344 Comparator | Sep → Nov 2008 | seasonal allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK835726 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00851344 ↗ |
| Action | Inhibit | “oral H1/H3 dual antagonist compound” NCT00605852 ↗ |
| Route | Oral | “single, escalating oral doses and repeat oral doses (7 days, once daily)” NCT00605852 ↗ |